JP2016526374A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016526374A5 JP2016526374A5 JP2016501252A JP2016501252A JP2016526374A5 JP 2016526374 A5 JP2016526374 A5 JP 2016526374A5 JP 2016501252 A JP2016501252 A JP 2016501252A JP 2016501252 A JP2016501252 A JP 2016501252A JP 2016526374 A5 JP2016526374 A5 JP 2016526374A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- amino acid
- particle
- seq
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 claims description 78
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 47
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 47
- 239000000427 antigen Substances 0.000 claims description 31
- 102000036639 antigens Human genes 0.000 claims description 31
- 108091007433 antigens Proteins 0.000 claims description 31
- 101710091045 Envelope protein Proteins 0.000 claims description 27
- 101710188315 Protein X Proteins 0.000 claims description 27
- 102100021696 Syncytin-1 Human genes 0.000 claims description 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 24
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 21
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 19
- 239000003446 ligand Substances 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 102000039446 nucleic acids Human genes 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 15
- 150000007523 nucleic acids Chemical class 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 210000000234 capsid Anatomy 0.000 claims description 14
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 12
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 11
- 108010087302 Viral Structural Proteins Proteins 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 10
- 208000035473 Communicable disease Diseases 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 7
- 201000009182 Chikungunya Diseases 0.000 claims description 6
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims description 6
- 230000003993 interaction Effects 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 206010014611 Encephalitis venezuelan equine Diseases 0.000 claims description 5
- 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 claims description 5
- 201000009145 Venezuelan equine encephalitis Diseases 0.000 claims description 5
- 241001502567 Chikungunya virus Species 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 241000710831 Flavivirus Species 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000000638 stimulation Effects 0.000 claims description 3
- 241000710929 Alphavirus Species 0.000 claims description 2
- 108090000565 Capsid Proteins Proteins 0.000 claims description 2
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 241000700605 Viruses Species 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 241000222122 Candida albicans Species 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 241000222722 Leishmania <genus> Species 0.000 description 2
- 241000235388 Mucorales Species 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 241000235389 Absidia Species 0.000 description 1
- 241000224422 Acanthamoeba Species 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- 208000006400 Arbovirus Encephalitis Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 241000223836 Babesia Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 241000223203 Coccidioides Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 241000223935 Cryptosporidium Species 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 201000001342 Fallopian tube cancer Diseases 0.000 description 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- 241000228402 Histoplasma Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101100407305 Homo sapiens CD274 gene Proteins 0.000 description 1
- 101100407307 Homo sapiens PDCD1LG2 gene Proteins 0.000 description 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 241000701460 JC polyomavirus Species 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046392 Ureteric cancer Diseases 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 201000008680 babesiosis Diseases 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 201000000220 brain stem cancer Diseases 0.000 description 1
- 208000032343 candida glabrata infection Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 102000048776 human CD274 Human genes 0.000 description 1
- 102000048119 human PDCD1LG2 Human genes 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 206010062261 spinal cord neoplasm Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361845712P | 2013-07-12 | 2013-07-12 | |
| US61/845,712 | 2013-07-12 | ||
| PCT/JP2014/069122 WO2015005500A1 (en) | 2013-07-12 | 2014-07-11 | Virus like particle comprising pd-1 antigen or pd-1 ligand antigen |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016526374A JP2016526374A (ja) | 2016-09-05 |
| JP2016526374A5 true JP2016526374A5 (enExample) | 2017-08-10 |
| JP6557208B2 JP6557208B2 (ja) | 2019-08-07 |
Family
ID=52277262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501252A Active JP6557208B2 (ja) | 2013-07-12 | 2014-07-11 | Ｐｄ−１抗原またはｐｄ−１リガンド抗原を含むウイルス様粒子 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9637532B2 (enExample) |
| EP (2) | EP3019600B1 (enExample) |
| JP (1) | JP6557208B2 (enExample) |
| KR (1) | KR20160029124A (enExample) |
| CN (1) | CN105358683A (enExample) |
| AR (1) | AR096885A1 (enExample) |
| AU (1) | AU2014288147B2 (enExample) |
| BR (1) | BR112016000303A2 (enExample) |
| CA (1) | CA2916458A1 (enExample) |
| IL (1) | IL243304B (enExample) |
| MX (1) | MX364952B (enExample) |
| TW (1) | TWI676636B (enExample) |
| WO (1) | WO2015005500A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX357202B (es) | 2012-02-16 | 2018-06-28 | Vlp Therapeutics Llc | Composicion de particula tipo virus. |
| TWI676636B (zh) | 2013-07-12 | 2019-11-11 | Ｖｌｐ醫療股份有限公司 | 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子 |
| US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| KR20200029627A (ko) | 2014-03-12 | 2020-03-18 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소 |
| US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
| US10385101B2 (en) | 2014-08-08 | 2019-08-20 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
| TWI720946B (zh) | 2014-08-08 | 2021-03-11 | 美商Ｖｌｐ醫療股份有限公司 | 包含改質套膜蛋白質ｅ３之類病毒粒子 |
| CA2960102C (en) | 2014-09-11 | 2023-10-24 | Vlp Therapeutics, Llc | Flavivirus virus like particle |
| RU2017132190A (ru) | 2015-03-18 | 2019-04-18 | Омнисайт | Гибридные белки, содержащие модифицированные поверхностные гликопротеины альфавируса и опухолеассоциированный антиген, и способы, связанные с ними |
| US10166281B2 (en) * | 2015-09-04 | 2019-01-01 | Vlp Therapeutics, Llc | Method and composition for modulating immune response |
| WO2018067361A1 (en) * | 2016-10-04 | 2018-04-12 | The Curators Of The University Of Missouri | Peptides for molecular detection of pd-l1 |
| WO2018161092A1 (en) | 2017-03-03 | 2018-09-07 | New York University | Induction and enhancement of antitumor immunity involving virus vectors expressing multiple epitopes of tumor associated antigens and immune checkpoint inhibitors or proteins |
| SG11201908528UA (en) | 2017-03-17 | 2019-10-30 | Vaximm Ag | Novel pd-l1 targeting dna vaccine for cancer immunotherapy |
| CN110636855B (zh) * | 2017-03-28 | 2024-08-09 | 俄亥俄州创新基金会 | 人pd1肽疫苗及其用途 |
| KR102823029B1 (ko) | 2017-12-20 | 2025-06-20 | 브이엘피 테라퓨틱스 인코포레이티드 | 알파바이러스 레플리콘 입자 |
| JP2021512966A (ja) * | 2018-02-07 | 2021-05-20 | イミュジーン、リミテッドＩｍｕｇｅｎｅ Ｌｉｍｉｔｅｄ | ワクチン組成物およびその使用 |
| FR3078536A1 (fr) * | 2018-03-05 | 2019-09-06 | Peptinov Sas | Composition vaccinale anti-pd-1 |
| EP3762023A4 (en) * | 2018-03-05 | 2021-12-29 | New York University | Induction and enhancement of antitumor immunity involving sindbis virus vectors expressing immune checkpoint proteins |
| FR3078535B1 (fr) * | 2018-03-05 | 2024-02-09 | Peptinov Sas | Composition vaccinale anti-pd-l1 |
| WO2020071869A1 (ko) * | 2018-10-05 | 2020-04-09 | 알엔에이진 주식회사 | 표적 세포 특이적으로 결합하여 다중 면역기능이 강화된 키메라항원 및 이의용도 |
| US12331096B2 (en) * | 2019-01-04 | 2025-06-17 | George Mason Research Foundation, Inc. | Binding domain mapping and compounds, compositions, complexes, methods, and kits related thereto |
| EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
| BR112022005044A2 (pt) * | 2019-09-17 | 2022-07-05 | Ohio State Innovation Foundation | Peptídeo quimérico, peptídeo sintético, composição farmacêutica, anticorpo, método de tratamento |
| CN111116733B (zh) * | 2019-11-28 | 2021-11-05 | 广东药科大学 | 一种靶向程序性死亡受体1和pd-1配体1相互作用界面的抗原肽和纳米抗体 |
| JP2023514825A (ja) * | 2020-02-26 | 2023-04-11 | ヴェルシテック リミテッド | コロナウイルス感染症に対するｐｄ－１ベースのワクチン |
| TWI891771B (zh) | 2020-04-17 | 2025-08-01 | 美商Ｖｌｐ醫療股份有限公司 | 冠狀病毒疫苗 |
| MX2022013638A (es) | 2020-04-30 | 2023-01-24 | Vlp Therapeutics Inc | Inmunoterapia con citocina. |
| EP4624487A1 (en) * | 2022-11-24 | 2025-10-01 | Tokushima University | Production of antibodies against protein |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8923123D0 (en) | 1989-10-13 | 1989-11-29 | Connaught Lab | A vaccine for human immunodeficiency virus |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| JP3954643B2 (ja) | 1991-11-16 | 2007-08-08 | グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム | マラリア原虫由来のＣＳおよびＨＢｓＡＧ間のハイブリッド蛋白質 |
| US5580773A (en) | 1992-06-17 | 1996-12-03 | Korea Green Cross Corporation | Chimeric immunogenic gag-V3 virus-like particles of the human immunodeficiency virus (HIV) |
| CA2143491C (en) | 1994-03-01 | 2011-02-22 | Yasumasa Ishida | A novel peptide related to human programmed cell death and dna encoding it |
| CA2232669A1 (en) | 1995-09-27 | 1997-04-03 | Frances Joanne Morling | Recombinant viruses incorporating a protease cleavable protein |
| CA2320958A1 (en) | 1998-02-11 | 1999-08-19 | Maxygen, Inc. | Antigen library immunization |
| ES2539411T3 (es) * | 1999-08-23 | 2015-06-30 | Dana-Farber Cancer Institute, Inc. | PD-1, receptor para la B7-4 y su utilización |
| US20110262389A1 (en) | 2001-02-13 | 2011-10-27 | Mosca Joseph D | Tumor-derived Biological Antigen Presenting Particles |
| CA2448908C (en) | 2001-05-30 | 2008-03-18 | Transgene S.A. | Adenovirus protein ix, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization |
| WO2003023026A1 (en) | 2001-09-06 | 2003-03-20 | Alphavax, Inc. | Alphavirus replicon vector systems |
| WO2003102166A2 (en) | 2002-02-26 | 2003-12-11 | Maxygen, Inc. | Novel flavivirus antigens |
| DE60334303D1 (de) | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| WO2004043399A2 (en) | 2002-11-13 | 2004-05-27 | The United States Of America As Represented By The Secretary Of The Navy | Methods and compositions for inducing immune responses and protective immunity by priming with alphavirus replicon vaccines |
| AU2003297041B2 (en) | 2002-12-13 | 2009-02-26 | Alphavax, Inc. | Alphavirus particles and methods for preparation |
| EP1608762B1 (en) | 2003-03-20 | 2014-01-08 | Alphavax, Inc. | Improved alphavirus replicons and helper constructs |
| MXPA05012754A (es) | 2003-05-29 | 2006-05-17 | Army Medical Res Inst For I | Vacunas virales atenuadas vivas para virus de encefalitis equina oriental. |
| CA2547511A1 (en) * | 2003-12-01 | 2005-07-28 | Dow Global Technolgies Inc. | Recombinant icosahedral virus like particle production in pseudomonads |
| PT1751289E (pt) * | 2004-05-18 | 2009-03-31 | Alphavax Inc | Vectores de alfavirais derivados da tc-83, partículas e métodos |
| BRPI0518146A (pt) | 2004-10-14 | 2008-10-28 | Crucell Holland Bv | kit de partes, uso de um adenovìrus recombinante defectivo na replicação, e, método de vacinação de um mamìfero para a infecção por malária |
| WO2006088229A1 (ja) | 2005-02-16 | 2006-08-24 | The Circle For The Promotion Of Science And Engineering | 改変されたウイルスカプシドタンパク質及びその使用 |
| DK1907000T4 (da) | 2005-06-08 | 2020-03-30 | The President And Fellows Of Harvard College | Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1). |
| GB0513421D0 (en) | 2005-06-30 | 2005-08-03 | Glaxosmithkline Biolog Sa | Vaccines |
| US20070104689A1 (en) | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
| CU23586A1 (es) | 2005-11-22 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus |
| EP2889309B1 (en) | 2006-03-03 | 2017-12-27 | Ono Pharmaceutical Co., Ltd. | Multimer of extracellular domain of pd-1 or pd-l1 |
| US7499304B2 (en) | 2006-07-31 | 2009-03-03 | Sandisk 3D Llc | Systems for high bandwidth one time field-programmable memory |
| AU2007291936B2 (en) | 2006-08-30 | 2012-09-27 | Artes Biotechnology Gmbh | Recombinant proteins and virus like particles comprising L and S polypeptides of avian hepadnaviridae and methods, nucleic acid constructs, vectors and host cells for producing same |
| GB2453155A (en) | 2007-09-26 | 2009-04-01 | Rolls Royce Plc | Co-axial pipe assembly which supplies oil to a bearing in a gas turbine engine |
| US20110035004A1 (en) | 2007-11-14 | 2011-02-10 | Maxwell G | Interfaced medical implant |
| WO2009079185A2 (en) | 2007-11-26 | 2009-06-25 | Novartis Vaccines And Diagnostics, Inc. | Methods of generating alphavirus particles |
| CN102317308A (zh) | 2008-11-26 | 2012-01-11 | 美国国有健康与人类服务部 | 类病毒组合物颗粒及其使用方法 |
| WO2011035004A1 (en) | 2009-09-18 | 2011-03-24 | Fraunhofer Usa Inc. | Virus like particles comprising target proteins fused to plant viral coat proteins |
| US8907053B2 (en) * | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| WO2012006180A1 (en) | 2010-06-29 | 2012-01-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv immunogens |
| KR101837219B1 (ko) | 2010-07-13 | 2018-03-09 | 데이진 가부시키가이샤 | 탄소섬유다발 및 그 제조 방법, 및 그로부터의 성형품 |
| WO2012023995A1 (en) | 2010-08-18 | 2012-02-23 | Takayuki Shiratsuchi | Modification of recombinant adenovirus capsid protein with immunogenic plasmodium circumsporozoite protein epitopes |
| WO2012106356A2 (en) | 2011-01-31 | 2012-08-09 | GOVERNMENT OF THE USA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES | Virus-like particles and methods of use |
| WO2012123755A1 (en) | 2011-03-17 | 2012-09-20 | The University Of Birmingham | Re-directed immunotherapy |
| CN103796676B (zh) | 2011-06-17 | 2017-09-12 | 伯哈拉特生物技术国际有限公司 | 包含灭活的基孔肯亚病毒株的疫苗组合物 |
| US9284356B2 (en) | 2011-07-12 | 2016-03-15 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Identification of a west nile virus CD4 T cell epitope and use thereof |
| CN102321639B (zh) | 2011-09-08 | 2013-06-26 | 中国疾病预防控制中心病毒病预防控制所 | 基孔肯雅病毒病毒样颗粒的制备方法和应用 |
| ES2918580T3 (es) * | 2011-10-17 | 2022-07-19 | Io Biotech Aps | Inmunoterapia basada en PD-L1 |
| PH12014500911A1 (en) | 2011-10-25 | 2014-06-09 | Florida Gulf Coast Univ Board Of Trustees | Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes |
| MX357202B (es) * | 2012-02-16 | 2018-06-28 | Vlp Therapeutics Llc | Composicion de particula tipo virus. |
| EP2834265A4 (en) | 2012-04-02 | 2015-10-14 | Univ North Carolina | METHOD AND COMPOSITIONS FOR DENGUE VIRUS EPITOPES |
| SMT201800368T1 (it) * | 2012-05-16 | 2018-09-13 | Immune Design Corp | Vaccini per l'infezione da virus-2 herpes simplex |
| SG11201509614SA (en) | 2013-06-03 | 2015-12-30 | Vlp Therapeutics Llc | Malaria vaccine |
| TWI676636B (zh) | 2013-07-12 | 2019-11-11 | Ｖｌｐ醫療股份有限公司 | 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子 |
| WO2015139784A1 (en) | 2014-03-18 | 2015-09-24 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Distinguishing flavivirus infection using a recombinant mutant envelope protein |
| TWI720946B (zh) | 2014-08-08 | 2021-03-11 | 美商Ｖｌｐ醫療股份有限公司 | 包含改質套膜蛋白質ｅ３之類病毒粒子 |
| US10385101B2 (en) | 2014-08-08 | 2019-08-20 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
| CA2960102C (en) | 2014-09-11 | 2023-10-24 | Vlp Therapeutics, Llc | Flavivirus virus like particle |
| US9363353B1 (en) | 2014-12-04 | 2016-06-07 | Hon Man Ashley Chik | Mobile phone docks with multiple circulating phone connectors |
| BR112017014219A2 (en) | 2014-12-31 | 2018-03-06 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | multivalent nanoparticle-based vaccines |
| JPWO2016199936A1 (ja) | 2015-06-12 | 2018-04-05 | 国立大学法人三重大学 | ヒトパラインフルエンザ２型ウイルスベクター及びワクチン |
| US10799575B2 (en) | 2015-06-25 | 2020-10-13 | Technovax, Inc. | Flavivirus and alphavirus virus-like particles (VLPS) |
| CA2992531C (en) | 2015-07-16 | 2023-09-26 | Bharat Biotech International Limited | Vaccine compositions |
| MA42502A (fr) | 2015-07-21 | 2018-05-30 | Modernatx Inc | Vaccins contre une maladie infectieuse |
| US10166281B2 (en) | 2015-09-04 | 2019-01-01 | Vlp Therapeutics, Llc | Method and composition for modulating immune response |
| WO2017150683A1 (en) | 2016-03-04 | 2017-09-08 | Vlp Therapeutics, Llc | Zika virus virus like particle |
| CN106085974B (zh) | 2016-06-07 | 2019-08-09 | 博奥生物集团有限公司 | 一种寨卡病毒假病毒颗粒及其制备方法 |
-
2014
- 2014-07-10 TW TW103123759A patent/TWI676636B/zh not_active IP Right Cessation
- 2014-07-10 US US14/328,268 patent/US9637532B2/en not_active Expired - Fee Related
- 2014-07-11 JP JP2016501252A patent/JP6557208B2/ja active Active
- 2014-07-11 KR KR1020167003373A patent/KR20160029124A/ko not_active Withdrawn
- 2014-07-11 MX MX2016000381A patent/MX364952B/es active IP Right Grant
- 2014-07-11 CN CN201480039571.4A patent/CN105358683A/zh active Pending
- 2014-07-11 WO PCT/JP2014/069122 patent/WO2015005500A1/en not_active Ceased
- 2014-07-11 BR BR112016000303A patent/BR112016000303A2/pt not_active Application Discontinuation
- 2014-07-11 EP EP14823398.4A patent/EP3019600B1/en active Active
- 2014-07-11 CA CA2916458A patent/CA2916458A1/en not_active Abandoned
- 2014-07-11 AR ARP140102570A patent/AR096885A1/es unknown
- 2014-07-11 EP EP19219213.6A patent/EP3666890A1/en not_active Withdrawn
- 2014-07-11 AU AU2014288147A patent/AU2014288147B2/en not_active Expired - Fee Related
-
2015
- 2015-12-23 IL IL243304A patent/IL243304B/en not_active IP Right Cessation
-
2017
- 2017-04-27 US US15/498,971 patent/US10464986B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Khairkhah et al. | Current and future direction in treatment of HPV-related cervical disease | |
| Zhang et al. | Peptide-based nanovaccines in the treatment of cervical cancer: a review of recent advances | |
| Ong et al. | Virus like particles as a platform for cancer vaccine development | |
| TWI676636B (zh) | 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子 | |
| Liu et al. | Polyacrylate-based delivery system for self-adjuvanting anticancer peptide vaccine | |
| Wu et al. | Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation | |
| JP4472724B2 (ja) | パピロマウイルス偽ウイルス及びその調製方法 | |
| JP6581101B2 (ja) | 局所免疫刺激及び全身免疫刺激の組み合わせによる癌の免疫療法 | |
| Daemen et al. | Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization | |
| JP2025023984A (ja) | コンジュゲート型ウイルス様粒子および抗腫瘍免疫リダイレクタとしてのその使用 | |
| JP2013150606A5 (enExample) | ||
| MXPA05009289A (es) | Conjugados de particulas tipo virus del analogo del peptido melan-a. | |
| JP2017523796A (ja) | 修飾エンベロープタンパク質ｅ３を含むウイルス様粒子 | |
| JP2009155338A5 (enExample) | ||
| Liu et al. | Self-adjuvanting therapeutic peptide-based vaccine induce CD8+ cytotoxic T lymphocyte responses in a murine human papillomavirus tumor model | |
| Jin et al. | Soft matter DNA nanoparticles hybridized with CpG motifs and peptide nucleic acids enable immunological treatment of cancer | |
| Li et al. | Surface-Functionalized Silica-Coated Calcium Phosphate Nanoparticles Efficiently Deliver DNA-Based HIV‑1 Trimeric Envelope Vaccines against HIV‑1 | |
| Glass et al. | Enhancing dendritic cell activation and HIV vaccine effectiveness through nanoparticle vaccination | |
| Murakami et al. | Human papillomavirus vaccines for cervical cancer | |
| JP2022520467A (ja) | 免疫活性もしくは癌の予防または治療用の医薬組成物 | |
| JP2014139185A5 (enExample) | ||
| Yang et al. | Buccal injection of synthetic HPV long peptide vaccine induces local and systemic antigen-specific CD8+ T-cell immune responses and antitumor effects without adjuvant | |
| Peacey et al. | Virus-like particles from rabbit hemorrhagic disease virus can induce an anti-tumor response | |
| Zhou et al. | MS2 virus-like particles as a versatile platform for multi-disease vaccines: a review | |
| CN113227121A (zh) | 通过特异性结合至靶细胞具有增强的多种免疫功能的嵌合抗原及其用途 |